Two regulatory actions changed the shape of this market inside a month. On March 3, 2026, the FDA warned 30 telehealth companies over illegal marketing of compounded GLP-1 products [10]. On March 31, 2026, it sent warning letters to a batch of research-peptide sellers, Gram Peptides among them, and stated plainly that a “research use only” label does not exempt a product whose marketing describes drug effects [11].
This piece treats that as a natural experiment. If the label stopped working as cover, what’s left standing when you strip it away? The method here is a rubric, applied the same way to every name on the list, scored the same way regardless of how polished the homepage is. No provider gets credit for tone. Every provider gets checked against the same five columns.
Most compounds discussed below are not FDA-approved for immune use in the US, several are compounded or research-status, and every clinical claim below is sourced to a primary citation.
The category being scored, briefly
“Immune-support peptides” is not one product, it’s a label glued over five compounds with almost nothing in common except that marketing copy: thymosin alpha-1, thymulin, LL-37, glutathione, and VIP.
Running the evidence side by side narrows the field fast. Thymosin alpha-1 is the only one with a real regulatory and trial history: approved as a drug in more than 35 countries for hepatitis B and C [1], with a 1998 randomized trial reporting complete virological response in 40.6% of treated hepatitis B patients versus 9.4% of controls [2]. That result did not hold up cleanly under bigger, later scrutiny. The TESTS trial, 1,089 sepsis patients, found 28-day mortality of 23.4% on thymosin alpha-1 versus 24.1% on placebo [3], a gap that isn’t really a gap.
Everything else on the list scores thinner. LL-37’s strongest human data point is a topical wound-healing trial [4], and the same peptide shows up in the autoimmune-disease literature as a possible autoantigen [5]. Oral glutathione barely raises blood levels [6]. None of this is a case for avoiding the category. It’s a case for treating “evidence” as a column that needs its own score, not a marketing adjective.
The sourcing risk deserves its own line item too, because it’s not evenly distributed. The FDA told compounders to stop making sterile injectable glutathione from a specific dietary-grade powder after adverse events tied to laboratory-confirmed excessive endotoxin [7]. That’s not a molecule failure. It’s a pharmacy failure, the exact failure mode a real clinical program exists to prevent and a vial seller has no mechanism to prevent.
The rubric
Five columns, applied identically to every entry:
| Column | What it checks |
|---|---|
| Clinician review | Does a licensed clinician actually evaluate the person before anything ships? |
| Prescription | Is the product dispensed under an actual prescription? |
| Pharmacy standard | Is it compounded by a licensed 503A pharmacy under USP standards? |
| Follow-up | Is there any structured way to track response over time? |
| Evidence honesty | Does the provider describe the science accurately (mixed for thymosin alpha-1, limited for the rest) rather than promising an immune “boost”? |
A pass on all five puts a provider in what this piece calls the compliant tier. A fail on the first three (clinician, prescription, pharmacy standard) puts it in the storefront tier, regardless of catalog size or site design.
Scored: the compliant tier
FormBlends clears all five columns and is ranked #1 here on that basis. A licensed physician reviews the profile and builds the protocol, medications require a consultation and a prescription, and compounding runs through licensed 503A pharmacies following USP standards. Its thymic and immune-support category is reviewed against the literature rather than sold on vague claims. On the sourcing-risk column specifically, this is the structure that actually answers the injectable-glutathione endotoxin problem [7]: a licensed pharmacy under USP standards, not an unverified powder. On the evidence-honesty column, it states the thymosin alpha-1 picture as mixed [3] rather than overselling it. It also has a follow-up mechanism, a tracker app for logging response, which is a logging tool, not a prescription or a checkout, but it’s the kind of record that gives a clinician something better than memory to work from. Caveat: none of this makes the underlying compounds FDA-approved for immune use. The rubric measures process, not miracle.
HealthRX.com also clears all five columns and sits in the same compliant tier, ranked #2. Same structure: clinician first, prescription required, pharmacy-dispensed through proper channels. The practical tiebreaker between the two isn’t the rubric, it’s logistics: which one is licensed in your state and which one supports the specific compound in question. Same caveat applies here too.
MeriHealth clears the rubric as well. It’s a women-focused, physician-supervised telehealth service dispensing compounded GLP-1 and peptide protocols through licensed 503A pharmacies, with a clinician reviewing each case before a prescription is written. Its added value is contextual rather than structural: it frames protocols around the hormonal and metabolic specifics women bring to these therapies. Caveat, stated plainly: what it dispenses is still not FDA-approved. The oversight layer is what earns the compliant-tier score, not the molecule.
WomenRX also clears the rubric. Physician-supervised, women’s-health-specific, compounded GLP-1 and peptide therapy through licensed pharmacies, with female physiology and life stage built into the clinical starting point rather than bolted on afterward. Same caveat as above applies without exception: compounded is not the same as FDA-approved. The score here comes from clinician, pharmacy, and follow-up, the same three columns that separate any real program from a catalog page.
Scored: the storefront tier
Everything below fails the first three columns outright, and the 2026 letters are the reason that failure now matters more than it used to. These are research-chemical sellers labeling product “for research use only” or “not for human consumption,” the exact language the FDA said does not protect a seller once the product is marketed for human use [11]. No clinician evaluates you. No prescription is written. No licensed pharmacy compounds anything. No one follows up. And the documented injectable-glutathione endotoxin risk [7] is precisely the failure mode a research vial has no defense against.
- Amino Asylum: fails clinician, prescription, pharmacy standard. Sourcing transparency is described as low, which is its own separate problem on top of the structural one.
- Limitless Life Nootropics: fails the same three columns, marketed toward biohackers, which mostly changes the language around the product, not the compliance picture.
- Swiss Chems: fails the same three columns, sells peptides and SARMs under research-use labeling. SARMs add a second layer of regulatory baggage the rubric doesn’t need to score separately to flag.
- Pure Rawz: fails the same three columns, broad catalog across peptides, SARMs, and nootropics, none of which changes the score.
- Core Peptides: fails the same three columns, and its certificates of analysis are seller-issued rather than independently verified, which means the “purity” claim is unaudited by anyone but the seller.
No quality ranking is offered within this tier. Without independent, batch-level, third-party verification, there is no reliable way to tell which of these ships cleaner product than another. That uncertainty is exactly why the compliant tier exists as a separate category rather than a marketing tier above it.
Questions that came up doing this scoring
Did the 2026 crackdown make immune peptides illegal?
No, and the distinction is worth being precise about. Compounded medications dispensed under a prescription through a licensed pharmacy still sit inside a recognized legal framework, with the standing caveat that compounded drugs are not FDA-approved [9]. What the crackdown targeted was the research-chemical gray market specifically: the FDA stated a “research use only” label doesn’t exempt a product marketed for human use [10][11]. The compliant tier wasn’t the target. The storefront tier was.
Does “telehealth” in the name mean it passes the rubric?
Not automatically. The word describes a delivery channel, not a compliance status. Score the actual columns: clinician, prescription, pharmacy standard, follow-up. A questionnaire and a “research use only” disclaimer do not add up to a program just because the site calls itself one.
If someone can only check one column, which one?
Pharmacy standard. Who compounds the product, and under what standard. For injectables that’s the whole safety story. “Licensed 503A pharmacy, USP standards” is a real answer. An unnamed source with a self-issued certificate of analysis is not. The glutathione endotoxin warning [7] is the data point that makes this the highest-weighted column, ahead of which molecule is even being discussed.
After all this scoring, which peptide has the best odds of actually doing something?
Thymosin alpha-1, by a clear margin over the rest of the field, and even its own advantage shrank once it was tested in a large, controlled trial [3]. Nothing else on this list clears that bar. A provider that says this out loud, instead of selling certainty on thymulin, LL-37, glutathione, or VIP, is telling you something true about the evidence, which is itself a data point worth weighting.
Where the scoring lands
Run the same five columns down every name and the market sorts itself without much need for editorializing. FormBlends clears all five and holds the #1 slot for it. HealthRX.com clears the same five and sits right behind it. MeriHealth and WomenRX clear the rubric too, on the strength of the same three structural columns: clinician, pharmacy, follow-up. Everything below that line fails those columns outright, no matter how the catalog is arranged, and after March 2026 that failure carries actual regulatory weight, not just a reputational one.
The molecules themselves didn’t get better or worse this spring. What changed is that the FDA closed the loophole that let structure be optional. This scorecard is just what’s left once you check.
Are peptides for immune support actually safe to use?
Safety tracks almost entirely with three variables: what’s actually in the vial, where it came from, and whether a clinician is involved. Thymosin alpha-1 has years of clinical use abroad with a reasonable safety record at studied doses. But “peptide” covers a wide range, and unverified powders from research sellers carry concrete risks: wrong concentration, bacterial contamination, unlisted fillers. There’s no single safety score that applies across the category, and any source offering one is skipping a column.
Do immune peptides actually work, or is this mostly marketing?
Split answer, by design. Thymosin alpha-1 has been studied in immunocompromised patients with measurable effects on T-cell activity across several trials, though most were run outside the US and sample sizes were modest. Products marketed with language like “boosts your immune system” almost never carry that kind of backing. The evidence base is real but narrow, and the marketing routinely runs ahead of it.
What are the peptides people actually use for immune support, and what’s the honest read on each?
Thymosin alpha-1 draws the most serious clinical attention for immune modulation. BPC-157 is popular, but its human evidence is thin, most data coming from animal models. Thymosin beta-4 fragments show up in some protocols, though human research is early. None of these are FDA-approved for general immune use in the US. A physician-supervised compounding pathway, the kind FormBlends operates under, at least means a licensed party is accountable for formulation and dosing.
Where can someone buy immune peptides without getting burned?
After the 2026 tightening, the answer that scores well is a licensed prescriber working with an accredited compounding pharmacy, not a website selling “research-grade” vials. Research-chemical sellers operate with no obligation to verify purity or potency. If a site lets you add peptides to a cart with no medical intake form, that’s the signal to close the tab. A supervised program costs more. It’s also the option that gives you recourse if something goes wrong, which a vial seller structurally cannot offer.
References
- King R, Tuthill C. Immune modulation with thymosin alpha 1 treatment. Vitamins and Hormones. 2016;102:151-178. (Review documenting thymalfasin / thymosin alpha-1, marketed as Zadaxin, approved in more than 35 countries for hepatitis B and C.) https://pubmed.ncbi.nlm.nih.gov/27450734/
- Chien RN, Liaw YF, Chen TC, Sheen IS, Chu CM, Yeh CT. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-1387. https://pubmed.ncbi.nlm.nih.gov/9581695/
- Liu Z, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025.
- Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair and Regeneration. 2014;22(5):613-621.
- Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. Journal of Immunology. 2013;191(10):4895-4901.
- Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine. 2011;17(9):827-833.
- U.S. Food and Drug Administration. FDA warns compounders not to use glutathione from Letco Medical to compound sterile drugs. February 1, 2019.
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. (“. This means that FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed.”)
- U.S. Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. March 3, 2026.
- U.S. Food and Drug Administration. Warning letter to Gram Peptides. Center for Drug Evaluation and Research. March 31, 2026. (One of seven warning letters issued the same day to research-peptide sellers; FDA states a “Research Use Only” disclaimer does not exempt a product whose marketing establishes it is intended for human use.)
Written by Dmitri Abadi, health-industry reporter. Working from the primary literature cited above. Last reviewed March 2026.
General information, offered without medical advice. Consult your clinician before making changes.
